Association Between TNF-α Polymorphisms and Cervical Cancer Risk: a Meta-analysis

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2011 Jun 15

PMID 21670964

Citations 19

Authors

Li Liu

Xi Yang

Xiaojun Chen

Tinjing Kan

Yan Shen

Zengyan Chen

Zhibin Hu

Affiliations

Soon will be listed here.

Abstract

Ga/gg: OR = 3.67, 95% CI = 1.25-10.81, P = 0.018). We also found that the variant genotypes -238GA/AA was associated with a significantly decreased risk of cervical cancer (GA/AA vs. GG: OR = 0.55, 95% CI = 0.41-0.74, P < 0.001). The results suggested that TNFA-308G/A and -238G/A may contribute to cervical cancer susceptibility.

Citing Articles

Small molecule inhibitors of the VEGF and tyrosine kinase for the treatment of cervical cancer.

Sarwar F, Ashhad S, Vimal A, Vishvakarma R Med Oncol. 2024; 41(8):199.

PMID: 38985225 DOI: 10.1007/s12032-024-02446-x.

Vaginal Microbiota and HPV in Latin America: A Narrative Review.

Tosado-Rodriguez E, Alvarado-Velez I, Romaguera J, Godoy-Vitorino F Microorganisms. 2024; 12(3).

PMID: 38543670 PMC: 10974203. DOI: 10.3390/microorganisms12030619.

The secretome as a biomarker and functional agent in heart failure.

Nyarko O, Sucharov C J Cardiovasc Aging. 2023; 3(3).

PMID: 37484982 PMC: 10361342. DOI: 10.20517/jca.2023.15.

The Correlation of Papanicolaou Smears and Clinical Features to Identify the Common Risk Factors for Cervical Cancer: A Retrospective and Descriptive Study from a Tertiary Care Hospital in Trinidad.

Umakanthan S, Bukelo M, Ghany S, Gay L, Gilkes T, Freeman J Vaccines (Basel). 2023; 11(3).

PMID: 36992281 PMC: 10052654. DOI: 10.3390/vaccines11030697.

Functional impact of allelic variations/haplotypes of TNF-α on reproductive tract infections in Indian women.

Sharma V, Sonkar S, Singhal P, Kumar A, Singh R, Ramachandran V Sci Rep. 2021; 11(1):627.

PMID: 33436768 PMC: 7803726. DOI: 10.1038/s41598-020-79963-y.

References

Deshpande A, Nolan J, White P, Valdez Y, Hunt W, Peyton C . TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis. 2005; 191(6):969-76. DOI: 10.1086/427826. View

CARSWELL E, Old L, Kassel R, Green S, Fiore N, Williamson B . An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975; 72(9):3666-70. PMC: 433057. DOI: 10.1073/pnas.72.9.3666. View

Calhoun E, McGovern R, Janney C, Cerhan J, Iturria S, Smith D . Host genetic polymorphism analysis in cervical cancer. Clin Chem. 2002; 48(8):1218-24. View

Jang W, Yang Y, Yea S, Lee Y, Chun J, Kim H . The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett. 2001; 166(1):41-6. DOI: 10.1016/s0304-3835(01)00438-4. View

Wilson A, Symons J, McDowell T, McDevitt H, Duff G . Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997; 94(7):3195-9. PMC: 20345. DOI: 10.1073/pnas.94.7.3195. View

Wang S, Bratti M, Rodriguez A, Herrero R, Burk R, Porras C . Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis. 2008; 199(1):20-30. PMC: 3690375. DOI: 10.1086/595563. View

Kaluza W, Reuss E, Grossmann S, Hug R, Schopf R, Galle P . Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol. 2000; 114(6):1180-3. DOI: 10.1046/j.1523-1747.2000.00001.x. View

Leibovich S, Polverini P, Shepard H, Wiseman D, Shively V, Nuseir N . Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature. 1987; 329(6140):630-2. DOI: 10.1038/329630a0. View

Gostout B, Poland G, Calhoun E, Sohni Y, Giuntoli 2nd R, McGovern R . TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol Oncol. 2003; 88(3):326-32. DOI: 10.1016/s0090-8258(02)00074-4. View

10.

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

11.

Zintzaras E, Ioannidis J . Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2004; 28(2):123-37. DOI: 10.1002/gepi.20048. View

12.

Kohaar I, Thakur N, Salhan S, Batra S, Singh V, Sharma A . TNFalpha-308G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population. Cell Oncol. 2007; 29(3):249-56. PMC: 4617819. DOI: 10.1155/2007/418247. View

13.

Strieter R, Kunkel S, Bone R . Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med. 1993; 21(10 Suppl):S447-63. DOI: 10.1097/00003246-199310001-00006. View

14.

Fong C, Siddiqui A, Mark D . Identification and characterization of a novel repressor site in the human tumor necrosis factor alpha gene. Nucleic Acids Res. 1994; 22(6):1108-14. PMC: 307937. DOI: 10.1093/nar/22.6.1108. View

15.

Bequet-Romero M . Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins. Biochem Biophys Res Commun. 2000; 277(1):55-61. DOI: 10.1006/bbrc.2000.3628. View

16.

Kroeger K, Carville K, Abraham L . The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997; 34(5):391-9. DOI: 10.1016/s0161-5890(97)00052-7. View

17.

Govan V, Constant D, Hoffman M, Williamson A . The allelic distribution of -308 Tumor Necrosis Factor-alpha gene polymorphism in South African women with cervical cancer and control women. BMC Cancer. 2006; 6:24. PMC: 1397852. DOI: 10.1186/1471-2407-6-24. View

18.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

19.

Hajeer A, Hutchinson I . Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum Immunol. 2001; 62(11):1191-9. DOI: 10.1016/s0198-8859(01)00322-6. View

20.

Dinarello C, Wolff S . The role of interleukin-1 in disease. N Engl J Med. 1993; 328(2):106-13. DOI: 10.1056/NEJM199301143280207. View